I3Y-MC-JPBK - ClinicalTrials.gov - NCT02152631
I3Y-MC-JPBK - ClinicalTrials.gov - NCT02152631
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC)
Participant must have a tumor with a KRAS mutation (this will be checked for at screening)
Participant must have received prior chemotherapy
Participants must NOT
Participant must not have an active infection with HIV, Hepatitis B or C, or a history of cardiac arrest
Female participant must not be pregnant or lactating
Trial Summary
Conditions the trial is for
Non-small Cell Lung Cancer, Solid Tumor
What the trial is testing?
Abemaciclib, Erlotinib
Could I receive a Placebo?
no
Enrollment Goal
450
Trial Dates
October 2014 - September 2021
Trial Phase
3
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC)
Participant must have a tumor with a KRAS mutation (this will be checked for at screening)
Participant must have received prior chemotherapy
Participants must NOT
Participant must not have an active infection with HIV, Hepatitis B or C, or a history of cardiac arrest
Female participant must not be pregnant or lactating
Trial Summary
Conditions the trial is for
Non-small Cell Lung Cancer, Solid Tumor
What the trial is testing?
Abemaciclib, Erlotinib
Could I receive a Placebo?
no
Enrollment Goal
450
Trial Dates
October 2014 - September 2021
Trial Phase
3
Trial Locations
Hide locations not currently recruiting